301331 恩威医药
已收盘 02-11 15:00:00
资讯
新帖
简况
恩威医药（301331）披露控股股东部分股份解除质押公告，2月5日股价上涨0.1%
证券之星 · 02-05
恩威医药（301331）披露控股股东部分股份解除质押公告，2月5日股价上涨0.1%
恩威医药（301331）披露控股股东询价转让结果公告，2月2日股价上涨0.11%
证券之星 · 02-02
恩威医药（301331）披露控股股东询价转让结果公告，2月2日股价上涨0.11%
股市必读：恩威医药（301331）1月27日董秘有最新回复
证券之星 · 01-28
股市必读：恩威医药（301331）1月27日董秘有最新回复
恩威医药最新公告：控股股东拟询价转让400万股股份
证券之星 · 01-26
恩威医药最新公告：控股股东拟询价转让400万股股份
恩威医药最新公告：2025年净利润同比预增50.68%至77.35%
证券之星 · 01-20
恩威医药最新公告：2025年净利润同比预增50.68%至77.35%
恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%
证券之星 · 2025-12-31
恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%
恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%
证券之星 · 2025-12-29
恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%
恩威医药：海南定安恩威实业有限公司与公司已无关联
证券之星 · 2025-12-24
恩威医药：海南定安恩威实业有限公司与公司已无关联
恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%
证券之星 · 2025-12-08
恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%
恩威医药：呼吸系统用药是公司重要的产品线之一
证券日报 · 2025-11-20
恩威医药：呼吸系统用药是公司重要的产品线之一
恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%
证券之星 · 2025-11-20
恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%
恩威医药：多款产品可用于流感治疗
证券之星 · 2025-11-20
恩威医药：多款产品可用于流感治疗
恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%
证券之星 · 2025-11-14
恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%
恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金
证券之星 · 2025-11-14
恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金
恩威医药（301331）2025年三季报简析：营收净利润同比双双增长
证券之星 · 2025-10-31
恩威医药（301331）2025年三季报简析：营收净利润同比双双增长
恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%
中金财经 · 2025-10-30
恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%
恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%
证券之星 · 2025-10-30
恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%
恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%
证券之星 · 2025-09-25
恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%
恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%
证券之星 · 2025-09-22
恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%
股市必读：恩威医药（301331）9月3日披露最新机构调研信息
证券之星 · 2025-09-04
股市必读：恩威医药（301331）9月3日披露最新机构调研信息
加载更多
公司概况
公司名称：
恩威医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、健儿药丸、山麦健脾口服液、化瘀舒经胶囊、益肺健脾颗粒、感冒舒颗粒。
发行价格：
29.80
{"stockData":{"symbol":"301331","market":"SZ","secType":"STK","nameCN":"恩威医药","latestPrice":29.6,"timestamp":1770793416000,"preClose":29.98,"halted":0,"volume":1977840,"delay":0,"changeRate":-0.0127,"floatShares":103000000,"shares":103000000,"eps":0.506,"marketStatus":"已收盘","change":-0.38,"latestTime":"02-11 15:00:00","open":30.08,"high":30.16,"low":29.52,"amount":58774600,"amplitude":0.0213,"askPrice":29.62,"askSize":18,"bidPrice":29.6,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.506,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770859800000},"marketStatusCode":5,"adr":0,"adjPreClose":29.98,"symbolType":"stock","openAndCloseTimeList":[[1770773400000,1770780600000],[1770786000000,1770793200000]],"highLimit":32.98,"lowLimit":26.98,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":102891887,"isCdr":false,"pbRate":2.85,"roa":"--","peRate":58.498024,"roe":"3.42%","epsLYR":0.3728,"committee":-0.251208,"marketValue":3046000000,"turnoverRate":0.0193,"status":1,"floatMarketCap":3040000000},"requestUrl":"/m/hq/s/301331","defaultTab":"news","newsList":[{"id":"2609301886","title":"恩威医药（301331）披露控股股东部分股份解除质押公告，2月5日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301886","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301886?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:35","pubTimestamp":1770302119,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，恩威医药报收于29.23元，较前一交易日上涨0.1%，最新总市值为30.08亿元。该股当日开盘29.49元，最高29.8元，最低29.0元，成交额达3315.42万元，换手率为1.1%。恩威医药于近日披露《关于控股股东部分股份解除质押的公告》。该笔股份质押起始日为2025年8月18日，质权人为徐英壮，质押用途为自身生产经营。本次解除质押后，恩威集团累计质押股份22,380,000股，占其所持股份86.97%，占公司总股本21.75%。公司表示该事项对生产经营、公司治理无不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2608123860","title":"恩威医药（301331）披露控股股东询价转让结果公告，2月2日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608123860","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608123860?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:52","pubTimestamp":1770043941,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，恩威医药报收于28.51元，较前一交易日上涨0.11%，最新总市值为29.33亿元。该股当日开盘28.4元，最高29.26元，最低28.39元，成交额达4552.78万元，换手率为1.53%。公司于近日披露《股东询价转让结果报告书暨持股5%以上股东权益变动触及1%整数倍的提示性公告》。本次权益变动后，出让方及一致行动人合计持股比例由69.10%降至65.22%。转让方式为非公开询价转让，不通过集中竞价交易，受让方锁定6个月。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2606734743","title":"股市必读：恩威医药（301331）1月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734743","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606734743?lang=zh_cn&edition=full","pubTime":"2026-01-28 02:21","pubTimestamp":1769538070,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，恩威医药报收于29.3元，下跌3.97%，换手率3.84%，成交量3.94万手，成交额1.16亿元。当日关注点来自交易信息汇总：1月27日主力与游资资金均呈净流出态势，散户资金净流入1582.71万元。参与报价的机构投资者共30家，有效认购股份数量为16,476,000股，有效认购倍数为4.12倍。本次询价转让不通过集中竞价或大宗交易方式进行，受让方6个月内不得转让所受让股份。本次转让不涉及公司控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2606210451","title":"恩威医药最新公告：控股股东拟询价转让400万股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2606210451","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606210451?lang=zh_cn&edition=full","pubTime":"2026-01-26 20:40","pubTimestamp":1769431244,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)公告称，公司控股股东成都恩威投资（集团）有限公司计划通过询价转让方式转让400万股股份，占公司总股本的3.89%，占剔除公司已回购股份后的总股本的3.93%。转让原因为自身资金需求。本次询价转让不通过集中竞价交易或大宗交易方式进行，受让方通过询价转让受让的股份，在受让后6个月内不得转让。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600032648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2604919937","title":"恩威医药最新公告：2025年净利润同比预增50.68%至77.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919937","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604919937?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:49","pubTimestamp":1768902585,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)披露2025年度业绩预告，预计2025年归母净利润为5650万元至6650万元，同比增长50.68%至77.35%。2025年业绩上升的主要原因是主营业务收入增长带来净利润增加及股权激励计划成本摊销减少。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000028682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2595782447","title":"恩威医药（301331）披露2025年中期分红派息实施公告，12月31日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595782447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595782447?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:11","pubTimestamp":1767175883,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，恩威医药报收于26.44元，较前一交易日上涨0.23%，最新总市值为27.2亿元。该股当日开盘26.42元，最高26.58元，最低26.25元，成交额达1840.99万元，换手率为0.68%。近日，恩威医药股份有限公司发布2025年中期分红派息实施公告。股权登记日为2026年1月7日，除权除息日为2026年1月8日。分红后将调整相关股东减持价格承诺及限制性股票授予价格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100033888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2595786735","title":"恩威医药（301331）披露2025年中期分红方案，12月29日股价下跌0.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595786735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595786735?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:46","pubTimestamp":1767001574,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，恩威医药报收于26.63元，较前一交易日下跌0.34%，最新总市值为27.4亿元。该股当日开盘26.85元，最高26.85元，最低26.38元，成交额达2190.56万元，换手率为0.8%。近日，恩威医药发布关于公司2025年中期分红方案的公告。根据公告内容，公司于2025年12月26日召开第三届董事会第九次会议，审议通过2025年中期分红方案。该方案在2024年年度股东会授权范围内，无需提交股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900024466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2593230954","title":"恩威医药：海南定安恩威实业有限公司与公司已无关联","url":"https://stock-news.laohu8.com/highlight/detail?id=2593230954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593230954?lang=zh_cn&edition=full","pubTime":"2025-12-24 11:37","pubTimestamp":1766547467,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药(301331)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下董秘，海南定安恩威实业有限公司跟贵公司有没有关联？恩威医药回复：您好！感谢您对公司的关注！海南定安恩威实业有限公司是公司控股股东恩威集团早期（上市前）在海南注册成立的经营实体，后随着恩威集团发展方向调整，逐步停止了该公司的运营，并于2018年转让了该公司全部股权。自此，海南定安恩威实业有限公司与公司已不存在任何关联关系。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400014719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2589435996","title":"恩威医药（301331）披露关于控股股东部分股份解除质押的公告，12月8日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589435996","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589435996?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:23","pubTimestamp":1765203819,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，恩威医药报收于28.77元，较前一交易日上涨0.03%，最新总市值为29.6亿元。公司近日发布公告称，接到控股股东成都恩威投资（集团）有限公司通知，其持有的4,000,000股公司股份已于2025年12月5日解除质押，占其所持股份比例13.45%，占公司总股本比例3.89%。截至公告日，恩威集团持有公司29,733,200股，占总股本28.90%；其一致行动人合计持股71,101,168股，累计质押股份50,420,836股，占其所持股份70.91%，占公司总股本49.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2584004133","title":"恩威医药：呼吸系统用药是公司重要的产品线之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2584004133","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584004133?lang=zh_cn&edition=full","pubTime":"2025-11-20 18:39","pubTimestamp":1763635140,"startTime":"0","endTime":"0","summary":"证券日报网讯恩威医药11月20日在互动平台回答投资者提问时表示，呼吸系统用药是公司重要的产品线之一，其中多款产品可用于缓解感冒症状：复方银翘氨敏胶囊、复方氨酚烷胺片、小儿氨酚黄那敏颗粒，另外，公司今年新推出的信心药业复产品种抗病毒口服液，包含板蓝根、地黄、连翘等9种中草药成分，具有清热祛湿，凉血解毒功效，可用于风热感冒，流感。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzst2619761.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-20/doc-infxzzst2619761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2584180024","title":"恩威医药（301331）股东成都恩威投资(集团)有限公司质押500万股，占总股本4.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180024","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584180024?lang=zh_cn&edition=full","pubTime":"2025-11-20 18:38","pubTimestamp":1763635112,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药11月20日公开信息显示，股东成都恩威投资(集团)有限公司向上海银行股份有限公司成都分行合计质押500.0万股，占总股本4.86%。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000029069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2584970652","title":"恩威医药：多款产品可用于流感治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2584970652","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584970652?lang=zh_cn&edition=full","pubTime":"2025-11-20 08:45","pubTimestamp":1763599517,"startTime":"0","endTime":"0","summary":"呼吸系统用药是公司重要的产品线之一，其中多款产品可用于缓解感冒症状：复方银翘氨敏胶囊、复方氨酚烷胺片、小儿氨酚黄那敏颗粒，另外，公司今年新推出的信心药业复产品种抗病毒口服液，包含板蓝根、地黄、连翘等9种中草药成分，具有清热祛湿，凉血解毒功效，可用于风热感冒，流感。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000004555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2583897507","title":"恩威医药（301331）披露2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市公告，11月14日股价下跌0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583897507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583897507?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:58","pubTimestamp":1763132301,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，恩威医药报收于32.37元，较前一交易日下跌0.77%，最新总市值为33.31亿元。近日，恩威医药发布关于2023年限制性股票激励计划第二个归属期第一批次归属结果暨股份上市的公告。公告显示，公司已于2025年11月14日完成该批次的归属登记，本次实际归属股票数量为76.02万股，占公司总股本的0.7388%。归属对象为105名激励对象，另有1名高级管理人员因避免短线交易暂缓归属。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2583729335","title":"恩威医药最新公告：拟出资2000万元与专业投资机构共同设立基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2583729335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583729335?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:30","pubTimestamp":1763116251,"startTime":"0","endTime":"0","summary":"恩威医药(301331.SZ)公告称，公司作为有限合伙人以自有资金认缴出资2000万元，参与设立嘉兴磐霖嘉颐创业投资合伙企业（有限合伙）。该基金规模为20100万元，投资方向包括医疗（创新药、创新医疗器械）及科技（企业级服务、硬科技）等。合伙企业尚需完成中国证券投资基金业协会备案和工商变更登记手续，实施过程存在不确定性。公司本次投资可能面临较长的投资回报期，以及投资项目不能实现预期收益或投资失败的风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400032547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2579645104","title":"恩威医药（301331）2025年三季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2579645104","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579645104?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:57","pubTimestamp":1761865074,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩威医药发布2025年三季报。根据财报显示，恩威医药营收净利润同比双双增长。截至本报告期末，公司营业总收入6.37亿元，同比上升13.65%，归母净利润3658.47万元，同比上升66.13%。去年的净利率为4.62%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100010434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2579112838","title":"恩威医药（301331）披露2023年限制性股票激励计划第二期归属条件成就，10月30日股价下跌4.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579112838","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579112838?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:41","pubTimestamp":1761820863,"startTime":"0","endTime":"0","summary":"近日，恩威医药发布关于2023年限制性股票激励计划第二期归属条件成就的公告。公司层面业绩考核方面，2024年营业收入较2022年增长17.43%，达到门槛值，公司层面可归属比例为80%；个人层面考核结果均为优秀/良好，归属比例为100%。董事会认为第二期归属条件已成就，同意办理相关归属手续。部分未达条件的限制性股票合计21.8821万股将被作废。本次归属不会导致公司总股本变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251030/31751796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2579113266","title":"恩威医药(301331)9月30日股东户数0.63万户，较上期减少13.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579113266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579113266?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:49","pubTimestamp":1761817792,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩威医药披露，截至2025年9月30日公司股东户数为6340.0户，较6月30日减少1008.0户，减幅为13.72%。在中药行业个股中，恩威医药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.35万户。从股价来看，2025年6月30日至2025年9月30日，恩威医药区间涨幅为0.06%，在此期间股东户数减少1008.0户，减幅为13.72%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2570034479","title":"恩威医药（301331）6979.02万股限售股将于9月25日解禁，占总股本67.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570034479","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570034479?lang=zh_cn&edition=full","pubTime":"2025-09-25 08:01","pubTimestamp":1758758517,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，恩威医药于9月25日将有6979.02万股限售股份解禁，为公司首发原股东限售股份，占公司总股本67.83%。本次解禁后，公司还有19.61万股限售股份，占总股本0.19%。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500003774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2569733127","title":"恩威医药（301331）披露关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告，9月22日股价上涨0.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569733127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569733127?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:48","pubTimestamp":1758552504,"startTime":"0","endTime":"0","summary":"公司近日发布《关于首次公开发行前已发行股份部分解除限售并上市流通的提示性公告》。公告显示，本次解除限售股东共5户，解除限售股份数量为69,790,184股，占公司总股本的67.83%，限售期为36个月。解除限售股份上市流通日期为2025年9月25日。本次解除限售后，公司有限售条件股份由69,986,254股减少至196,070股，无限售条件股份由32,905,633股增加至102,695,817股，总股本不变。保荐机构对本次解除限售无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200035037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2564950319","title":"股市必读：恩威医药（301331）9月3日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2564950319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564950319?lang=zh_cn&edition=full","pubTime":"2025-09-04 04:04","pubTimestamp":1756929857,"startTime":"0","endTime":"0","summary":"截至2025年9月3日收盘，恩威医药报收于33.97元，下跌2.86%，换手率4.2%，成交量1.38万手，成交额4759.37万元。来自机构调研要点：2025年上半年归母净利润同比增长113.80%，主要得益于河南信心药业重点产品复产上市、线上非药类产品销售增长及摊销费用下降。公司收购河南信心药业是战略布局的关键一步，旨在拓展产品矩阵及市场覆盖，从而提升业绩水平。截至目前，公司尚未获悉大股东及其一致行动人关于减持其所持有股份意向的通知或信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090400002890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770815618439,"stockEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0392},{"period":"3month","weight":-0.0445},{"period":"6month","weight":-0.1289},{"period":"1year","weight":0.2734},{"period":"ytd","weight":0.1482}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0019},{"period":"3month","weight":0.0321},{"period":"6month","weight":0.126},{"period":"1year","weight":0.2427},{"period":"ytd","weight":0.0402}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"恩威医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6340人(较上一季度减少13.72%)","perCapita":"16198股","listingDate":"2022-09-21","address":"西藏自治区昌都市卡若区经开区A坝区创业大道恩威大厦","registeredCapital":"10289万元","survey":" 恩威医药股份有限公司的主营业务是中成药、化学药及健康私护用品的研发、生产及销售。公司的主要产品是洁尔阴洗液、洁尔阴软膏、洁尔阴泡腾片、健儿药丸、山麦健脾口服液、化瘀舒经胶囊、益肺健脾颗粒、感冒舒颗粒。","listedPrice":29.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩威医药,301331,恩威医药股票,恩威医药股票老虎,恩威医药股票老虎国际,恩威医药行情,恩威医药股票行情,恩威医药股价,恩威医药股市,恩威医药股票价格,恩威医药股票交易,恩威医药股票购买,恩威医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}